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Abstract
Schizophrenia is a neuropsychiatric illness without known etiology or cure. Current efforts
for symptom treatment still seem to leave a large portion of affected individuals without
proper symptom management, with those experiencing symptom relief still having to wrestle
with potential side-effects from medication trials. There has been growing evidence
suggesting that glutamate and glutathione abnormalities hold major roles in development and
manifestation of schizophrenia symptoms.
Magnetic resonance spectroscopy (MRS) provides a non-invasive means to observe in-vivo
brain chemistry, including glutamate and glutathione. By adding a functional component to
an MRS paradigm (fMRS), such as the color-word Stroop task, it is possible to detect
potential changes in brain metabolite levels in response to a cognitive stimulus.
The objectives of this thesis were to determine whether a conventional short echo-time or
longer echo-time semi-LASER sequence would be more suitable for measurements of an
fMRS paradigm at 7.0-Tesla, and to apply this finding to the study of a group of nevermedicated, first-episode schizophrenia (FES) individuals to track any potential abnormal
glutamate and glutathione dynamics.
Contrary to previous beliefs that the shortest achievable echo-time would produce the most
measurement signal, results from this study found that a long echo time (TE=100ms)
produced very similar quality of measurements, with further benefits of long echo time being
the removal of any macromolecular signal contribution.
Comparison of healthy controls (n = 25) to a FES population (n = 21) revealed no significant
difference in resting or dynamic glutamate levels. However, resting and dynamic glutathione
level were significantly different, suggesting potential glutathione regulation abnormalities,
and, in extension, although not observed in this study, potential glutamate and glutamine
abnormalities.
Future fMRS studies should investigate glutamate and glutathione dynamics from
longitudinal data of FES follow-ups as well as between specific sub-groups within FES.
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Summary for Lay Audience
Schizophrenia is an illness that affects the human brain and mind. Patients often hear voices
and hold delusional beliefs. They often lack motivation and have trouble with attention and
memory. Currently, there is no known cure or clear knowledge of its cause(s). Symptom
treatment typically involves administering medication that regulates a brain chemical called
dopamine. However, a large portion of patients do not respond to these medications, and
after a few unsuccessful trials, this subgroup, declared non-responders, will be given
Clozapine, which indirectly acts on another brain chemical called glutamate. Because of its
side effects, Clozapine is left as a last resort. For non-responders, finding their way to an
effective medication can be long and costly, usually leading to prolonged patient suffering
and disability.
Measurements of brain chemicals glutamate and glutathione early in the illness have been
shown, at resting levels, to potentially distinguish responders from non-responders. However,
these measurements had not taken into account that brain glutamate levels change depending
on the amount of brain activity, and so, we used functional magnetic resonance spectroscopy
(fMRS) to measure changes of glutamate and glutathione levels in the brain during the
performance of a task, the same specific brain activity for all participants. We believe these
measurements will improve our ability to identify non-responders even before treatment
begins.
This work shows that never medicated, first-episode patients with schizophrenia did not
change glutamate levels significantly during the task, but did change glutathione levels
differently compared to a cohort of healthy control individuals, which gives us hints about
the chemicals involved in task difficulties and how to possibly treat them.
We hope that future work descending from these results will help psychiatrists develop ways
to identifying non-responders upon first admission, and choose the right medication without
delay.
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Chapter 1

1

Introduction

This thesis contains work that investigates neuroimaging in mental illness, specifically
schizophrenia. Mental illnesses are those that affect an individual’s mood, thinking, or
behavior and can be a major concern when symptoms and stress start affecting a person’s
ability to function in everyday life. Schizophrenia is a complex disorder that affects
around 1% of the population in Canada and worldwide1,2 and though the experience of
the illness can vary from individual to individual, there is a potential for serious decline
in quality of life if left untreated3–5. Currently, there is no known cure for schizophrenia
as the exact causes and mechanisms of the illness are largely unknown. Hence, symptom
management through various treatments remains the best hope for individuals with this
illness. Early intervention in schizophrenia has been shown to greatly improve symptom
treatment outcomes in individuals with hope of returning to normal functioning and
lifestyles in society6,7. While many illnesses and disorders are studied using definitive
anatomical and physiological abnormalities to explain the causes of observed symptoms8–
13

, the lack of strong anatomical or physiological basis to fully explain the etiology of

schizophrenia steered schizophrenia research to focus on potential mechanisms
responsible for the symptoms observed in hopes that finding these chemical pathways
will grant understanding as to which parts of the brain and in what form of brain
abnormalities would cause the illness of schizophrenia14–16.

1.1 Schizophrenia
1.1.1

Illness and Symptoms

Schizophrenia is an illness of the mind and brain, affecting an individual’s thoughts,
emotions, and behavior. The illness is believed to have both genetic and environmental
contributions16, including neurodevelopmental contributions where complications in early
brain development remain dormant until symptoms typically start manifesting in the late
teens to early twenties of an individual’s life17. Though the exact cause of schizophrenia
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is unknown, research has shown that certain factors increase the risk of illness
development including having close family members with schizophrenia17,18,
experiencing complications at time of birth18–20, experiencing social stress21,22, and using
cannabis early in youth23,24.
Schizophrenia is characterized by a complex combination of positive, negative, and
cognitive symptoms25–27. Positive symptoms refer to characteristics in individuals that
appear added or distorted in reference to a healthy control population such as having
hallucinations or delusions. Negative symptoms describe characteristics that seem
reduced or lost and include traits such as social withdrawal, lack of emotions, or reduced
motivation in everyday life. Lastly, cognitive symptoms describe any difficulties with
attention, concentration, or memory and include having disorganized speech or thought.
Not everyone with schizophrenia will experience the same combination of symptoms
though certain symptoms have been shown to cluster together more than others25.
Schizophrenia should be considered a major social issue because the social stigmas
arising from a lack of public knowledge about those affected can not only be debilitating
and demoralizing to patients and their families, but can also reduce access to care for
other conditions that may be present28. Furthermore, experiencing symptoms that distort
one’s functional and social abilities can lead to hardships in societal integration29 as well
as affect an individual’s enjoyment to a quality of life that would otherwise be granted if
not for their illness30. Since some symptoms of schizophrenia fall into danger of
potentially being easily dismissed erroneously, such as thinking that a child is simply lazy
or introverted instead of seeing them as warning signs for schizophrenia development, it
is important to establish reliable markers for early detection and proper diagnosis in
schizophrenia so that appropriate care and treatment may be provided.

1.1.2

Diagnosis and Treatment

Diagnosis of schizophrenia usually involves multiple tests and screening along with
certain criteria having to be met before full diagnosis of schizophrenia can be made.
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Healthcare providers will look to rule out brain tumors, substance abuse, or other
psychiatric disorders, such as bipolar disorder or major depressive disorder. According to
the fifth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5)31, if
two or more of the following symptoms persist over a period of six months, a diagnosis
of schizophrenia is appropriate: delusions, hallucinations, disorganized speech or
catatonic behavior, negative symptoms, occupational or social dysfunction. After a
trained physician completes the appropriate screenings and psychiatric evaluations,
diagnostic criteria for schizophrenia can be made.
Currently, the first-line treatment for individuals with schizophrenia involves
administration of antipsychotic medication that act on the dopamine pathways in the
brain32. Though some individuals require additional medication trials using different
antipsychotic medications, this first-line treatment generally helps to relieve and manage
the positive symptoms of schizophrenia32. However, around 30% of individuals who
receive this care will not respond to the antipsychotic medication and will have persisting
positive symptoms along with negative and cognitive symptoms33–36. If treatment remains
ineffective even after two additional antipsychotic medication trials, a drug called
clozapine is usually suggested. Clozapine is often highly effective in reducing
schizophrenia symptoms but is usually the last-line treatment due to its adverse side
effects, one serious effect being a decrease in white blood cell count and an increase in
risk for infection33. Studies have suggested that clozapine can affect glutamate regulation
in the brain and is perhaps why its administration shows different treatment responses
than other dopamine-based antipsychotics in the 30% of treatment-resistant individuals37–
40

.

1.1.3

Glutamate and Glutathione

Glutamate is the human brain’s most abundant excitatory neurotransmitter and has been
hypothesized to play a role in symptoms observed in schizophrenia41–43. Drugs such as
ketamine and phencyclidine (PCP), when administered in subanasthetic doses, have
produced a full range of positive, negative, and cognitive symptoms of schizophrenia44.
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Ketamine and PCP are known N-methyl-D-aspartate (NMDA) glutamate receptor
antagonists44,45 giving rise to the glutamate NMDA hypofunction hypothesis of
schizophrenia, or glutamate hypothesis of schizophrenia, which states that interference or
blockage to the NMDA receptors promote glutamate release and possible excess46.
Having excess glutamate in the brain can lead to neurotoxicity and oxidative stress and
without proper homeostatic regulations, could lead to neural dysfunction and death47–49.
Normally, glutathione (GSH) functions as the brain’s first-line of defense against
oxidative stress and works to protect any neuronal damage from free radicals. There is
evidence to suggest that schizophrenia may be associated with the brain’s inability to
synthesize and regulate glutathione, without which, free radicals and glutamate excess
would only keep increasing toxicity in the brain48,49. Studies have also shown that
glutathione depletion may lead to NMDA hypofunction47–49, suggesting that redox
dysregulation and NMDA hypofunction in schizophrenia are tightly linked through a
reciprocal relationship.
While resting measurements of glutamate and glutathione have revealed great insight as
to potential physiological mechanisms behind schizophrenia symptoms, studying the
dynamic regulations of these metabolites in individuals may provide another large piece
of the puzzle toward understanding schizophrenia.

1.2 Neuroimaging
Many imaging modalities are available for the wide range of brain studies currently under
investigation, each with their advantages and disadvantages. For the purposes of this
thesis, magnetic resonance imaging (MRI) and spectroscopy (MRS) were chosen to
investigate our research questions because of the following advantages: first, for a
volunteer population that include individuals who experience psychosis or other
symptoms triggered by stress or worry, MRI being free of ionizing radiation would
encourage individuals to participate in our study as well as reduce worry of any potential
side-effects from imaging. Secondly, MRI scanners are able to obtain a variety of
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imaging information that allows for correlation and combination studies. This study was
part of a larger study called TOPSY (Tracking Outcomes in Psychosis) where imaging
sequences apart from anatomical imaging and spectroscopy were obtained from our
volunteers to be used in the future (DTI and resting-state fMRI), but were not included
for the purposes of this study. To understand the study design and tools used for this
study, it is necessary to look into basic nuclear magnetic resonance (NMR) physics.

1.2.1

Nuclear Magnetic Resonance (NMR)

The first component of NMR to understand is that we are dealing with fundamental
properties of atomic nuclei, more specifically, a fundamental property of particles within
atoms (protons, neutrons, electrons), that we call nuclear spin angular momentum, S
(Figure 1-1). A non-zero spin value in a nucleus will give rise to a magnetic moment, 𝝁,
of a nucleus, and can be expressed by,
𝝁 = 𝛾ℏ𝑺

…… (1)

where, 𝛾 is the gyromagnetic ratio and ℏ is the Planck’s constant (ℎ) divided by 2𝜋.
Atoms that possess an odd mass number or even mass number with odd number of
protons and neutrons will have non-zero spin values. However, atoms with even mass
number and even atomic number will possess zero spin with zero magnetic moment.
The next component of NMR involves the interaction of nuclear magnetic moments with
an external magnetic field, B0 (Figure 1-1). Quantum mechanics reveals that for a given
spin, S, and magnetic field, B0, the Zeeman energy, E, which is the energy associated
with the interaction between the magnetic moment and an external magnetic field, can be
expressed as,
𝐸 = −𝝁 ∙ 𝑩𝟎 = −𝛾ℏ𝑺 ∙ 𝑩𝟎

…… (2)

Furthermore, using the spin state quantum number, ms, to represent values from -S, -S+1,
…, +S, all the different nuclear energy levels can be expressed by,
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𝐸 = −𝛾ℏ𝑚𝑠 𝐵0 = ℏ𝜔0 𝑚𝑠

…… (3)

where 𝜔0 , also known as the Larmor frequency, is equal to,
𝜔0 = −𝛾𝐵0 = 2𝜋𝑓0

…… (4)

For the purpose of this thesis, all further mentions of nucleus will refer to the hydrogen
(1H) nucleus, and by extension, a spin value of S=1/2. The Larmor frequency describes
the rate of precession of a proton (for 1H-NMR) about an external magnetic field and is
directly proportional to the strength of B0. In the case of hydrogen nuclei, there are two
energy states, lower energy and higher energy states. Since the Larmor frequency is
dependent on B0, the energy difference based on Equation (3) of the two energy levels
will also be dependent on the main magnetic field.

Figure 1-1 Effect of external magnetic field on nuclei
(left) For a sample of nuclei in thermal equilibrium, all nuclei will be in random
orientation and will result in no net magnetization. (right) When an external
magnetic field, B0, is introduced, the nuclei will begin precession around B0 and
induce a net bulk magnetization that can be measured.

7

The final component of NMR involves using resonance to induce spin state and energy
level transitions. At the resonant frequency, nuclei are able to absorb energy to reach a
higher energy state or dissipate energy to reach a lower energy state (Figure 1-2). In the
presence of a static magnetic field in thermal equilibrium, the relative number of protons
in each of the two energy states can be described by the Boltzmann distribution, which
describes the balance between the tendency of spins to settle in the lower energy state and
the pressure from thermal collision to produce random transitions between energy states,
thereby equalizing the populations. In practice, there is a very small excess in the number
of protons in the lower energy state (~23∙10-6 of total, at 7.0T), meaning that a large
number of magnetic moments are necessary for detectable changes in bulk magnetization
to be measured. This excess fraction of spins in the lower energy state is directly
proportional to the main magnetic field strength, B0, with higher field strength helping
more spins to remain in the lower energy state, and thereby playing a role in improved
SNR at higher field strengths.

Figure 1-2 Spin energy states
(left) Nuclear energy levels are quantized and the difference in the two energy states
will be associated with a specific frequency according to equation (3). (right) The
frequency of each nuclei can then be represented in a spectrum of frequencies.
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1.2.2

Magnetic Resonance Spectroscopy (MRS)

Using the properties of NMR, it is possible to use radiofrequency (RF) pulses to excite a
specific volume, or voxel, of nuclei and attain a spectral signature of its contents. This
technique is called magnetic resonance spectroscopy and it can be used to observe in-vivo
human brain metabolites and their relative concentrations. MRI scanners are largely
composed of the main magnet, which determines the main magnetic field strength, the
gradient coils, which distorts the main magnetic field slightly in predictable ways, and the
shim coils, which functions to adjust and improve field inhomogeneity. For voxel
localization, RF pulses are applied with slice-selective gradients in three orthogonal
planes. MRS signal will only be generated from the spins in the cubic (or rectangular
prism) region of space formed by the intersection of these three planes.
In a homogenous B0, each nucleus will experience a slightly different total magnetic field
due to the varying degree of shielding provided by the atom’s electron cloud. This means
that different molecular geometries, including bond lengths and bond angles, will
contribute to the slight change of total magnetic field experienced by a particular nucleus,
and by extension, its resonant frequency. This phenomenon is called chemical shift and
helps distinguish nuclei from different molecules. Spectral signatures are often displayed
in terms of chemical shift in units of ppm (parts-per-million) with peak intensity
reflecting the relative number of equivalent 1H within each molecule.
Since NMR detects frequency, the following equation is used to convert frequency in
Hertz into chemical shift, 𝛿, in ppm,
𝛿(𝑝𝑝𝑚) = 106 ∙

𝑓−𝑓𝑟𝑒𝑓
𝑓𝑟𝑒𝑓

…… (5)

where f is the measured frequency of the nucleus under observation and fref is a reference
frequency, usually DDS (4,4-dimethyl-4-silapentane-1-sulfonic acid), a compound
widely used for spectroscopy calibrations due to its water-solubility and intense proton
signal peak found much upfield than most organic molecular signals. The DDS peak is
assigned a specific ppm value of 0. Another reference, especially in the human brain, is
the NAA CH3 peak, which is typically assigned a value of 2.01ppm. This is a useful way
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of looking at spectra because different magnetic field strengths will yield different
resonant frequencies according to equation 4 and so the distance between two nuclear
peaks may appear different in one field strength as opposed to another. Using chemical
shift ppm can eliminate magnetic field dependence in observation of singlet resonances
and help to avoid confusion and facilitates consistency in spectral comparisons between
various field strengths.
Several spectroscopy methods (or sequences) exist that are derivatives of using echoes of
the free-induction-decay (FID) to make measurements. A few common sequences include
PRESS (point-resolved spectroscopy), LASER (localized by adiabatic selective
refocusing), semi-LASER, and STEAM (stimulated echo acquisition mode)50. By using
different RF pulse schema, these sequences provide different advantages as tools for
spectroscopy measurement. For example, STEAM employs a 90°-90°-90° pulse scheme
that allows for very short echo time acquisitions, hence allowing for less signal loss due
to T2, T2*, and J-dephasing. PRESS (90°-180°-180°) and semi-LASER (90°-180°-180°180°-180°) are spin-echo derived and have higher SNR per spectrum compared to
STEAM (for a given echo time). This study will utilize the semi-LASER pulse sequence
for its advantages over other sequences: 1) being more tolerant of B1 inhomogeneity; 2)
allowing a more precise excitation profile of the voxel (without unwanted signals from
beyond the targeted voxel)50. Other techniques such as the use of J-editing or quantum
filtering were considered but not utilized because of sensitivity to motion, signal-to-noise
ratio loss from subtraction methods, and general low signal yield51,52.

1.2.3

Functional MRS (fMRS)

The mechanics of NMR and MRS can be taken further to study brain metabolite
dynamics using functional MRS (fMRS) (Figure 1-3). As opposed to resting MRS which
measures the molecular concentration levels during an assumed “resting state” (Figure 13), fMRS measures the molecular levels across a time course that includes a controlled
resting baseline as well as a stimulus section (Figure 1-4). Various stimuli are available
for an fMRS paradigm, such as visual53–55, cognitive task56,57, or sensory pain stimuli58,59.
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Returning to our sample of individuals with schizophrenia, using a cognitive battery task
during an fMRS paradigm may reveal any existing abnormal brain metabolite regulation.
An issue of resting MRS studies is that all spectra are averaged together regardless of the
cognitive state of participants and without any instructions given regarding their
cognitive state37. Functional MRS deals with this issue by averaging by state and with
instructions being given for both the rest and task states. Typical resting instructions
would include gaze fixation and keeping the mind wandering without focusing on any
particular topic for any length of time. Using this dynamic scale might be a more suitable
marker for detecting and studying schizophrenia.

Figure 1-3 Example of resting MRS spectra and metabolites of interest
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Illustration of spectral signatures of metabolites of interest. Spectrum was obtained
using 7.0-Tesla MRS semi-LASER pulse sequence at TE=100ms. The sum of all
individual metabolite spectral signatures produces the overall spectrum represented
by ‘Data’ (light grey) line.

Figure 1-4 Example of fMRS time course
Sample illustration of an fMRS time course. As opposed to a single spectrum in
static MRS, fMRS uses several spectra collected over a given time course, each
representing part of a non-stimulus rest state or stimuli-introduced functional state.

1.3 Thesis Overview
The following two chapters of this thesis are works that look into the effects of glutamate
and glutathione levels in individuals with first-episode schizophrenia. Chapter 2 is a
methodological study investigating parameter optimization for functional magnetic
resonance spectroscopy measurements at 7-Tesla. Chapter 3 is a direct application of the
tools and methods established in the previous chapter to study glutamate and glutathione
dynamics in a never-medicated first-episode schizophrenia population. The overall aim of
this thesis is to study the dynamic glutamate and glutathione behaviors upon functional
cognitive stimuli and recovery to baseline to better understand any potential glutamate
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and glutathione regulation abnormalities in the brains of individuals with schizophrenia.
Based on previous fMRS work in schizophrenia56,57, we predict that the first-episode
schizophrenia group will have elevated glutamate and lower glutathione levels compared
to a healthy control population and that metabolite regulation abnormalities upon
functional activation will be present in the form of delayed increases of lower amplitude
in both metabolites (Figure 1-5). Once stimuli are removed, we expect to see a return to
baseline in metabolite concentration levels.

Figure 1-5 Illustration of expected metabolite abnormalities
Given a sample functional stimulus on/off pattern in (a), as was used in Taylor et al.
201556, we expect abnormalities in metabolite regulation (b) in the forms of (1) lower
amplitude and (2) delayed response (indicated by the red line). The black line
represents expected healthy metabolite behavior.
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Chapter 2

2

Observing metabolite changes in short versus long
echo time functional magnetic resonance spectroscopy
at 7-Tesla

This work is a methodological study examining healthy control volunteers to determine
the optimal functional magnetic resonance spectroscopy parameters to use for future
clinical studies involving individuals with schizophrenia.

2.1 Introduction
Proton magnetic resonance spectroscopy (1H-MRS) has been instrumental in clinical and
research settings for observing in-vivo human molecular chemistry. Studies involving
brain magnetic resonance imaging (MRI) and MRS have especially pushed the
boundaries of how we can study the human brain and increase our understanding of brain
mechanisms on a chemical level. This is important particularly for mental illnesses such
as schizophrenia where the exact pathophysiological mechanisms responsible for
symptoms remain in question.
Schizophrenia symptoms are largely categorized into positive, negative and cognitive
symptoms and individuals with schizophrenia may experience any combination of these
symptoms in varying degrees. Current first-line treatment methods include the
administration of antipsychotics that act on the dopaminergic pathways of the brain and
have been useful for managing the positive symptoms of schizophrenia in many patients1.
However, around a third of people with schizophrenia do not seem to get better with this
first-line treatment suggesting an alternative or additional pathway responsible for the
negative and cognitive symptoms experienced by these individuals2-5. One leading
hypothesis is the N-methyl D-aspartate (NMDA) hypofunction hypothesis, which
proposes that the NMDA glutamate receptors’ reduced functioning is the cause of the
symptoms of this illness. Previous findings that support this hypothesis involve
administering subanesthetic doses of phencyclidine (PCP) and ketamine, both NMDA
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receptor antagonists, to subjects to find that the full range of schizophrenia symptoms
was replicated, including negative and cognitive symptoms6,7.
Though postmortem studies have found similar results in the past, the rapid changes of
proteins after death put constraints on how brain molecular chemistry can be studied.
MRS offers a solution to such constraints, as we are now able to observe in-vivo human
brain metabolites non-invasively without the use of any harmful ionizing radiation. Much
attention has been drawn to studying glutamate in the human brain in hopes to prove
glutamatergic contribution in the pathophysiology of the full range of schizophrenia
symptoms8-12. For example, elevated resting glutamate levels in individuals with
schizophrenia may suggest NMDA receptor hypofunction as well as glutamate
excitotoxicity due to excess13,14. This has extended to studies of related metabolites such
as glutathione (GSH), an important antioxidant in the human body, which may provide
protection against oxidative stress in the brain15,16. Conversely, inability to regulate GSH
properly may make brain excitotoxicity worse, possibly linking the two metabolites to
symptoms observed in non-responding patients with schizophrenia. Finding the
mechanisms responsible for negative and cognitive symptoms could help distinguish
those who are treatment responders to the first-line medication from those who are
treatment-resistant to dopamine-based drugs. Since earlier treatment has been linked to
better patient symptom outcome in schizophrenia, individuals falling in the treatmentresistant group would benefit from finding the right treatment plan earlier rather than
suffering a prolonged period of time under an ineffective first-line treatment only to find
later that they would have to find alternative treatment methods17,18.
Previous work by Egerton et al. (2012)9 showed that abnormal resting glutamate levels
were linked to poor treatment outcome in first-line treatments. However, since glutamate
is the brain’s main excitatory neurotransmitter, various brain activities are able to alter
glutamate levels, especially if the resting state is not well controlled for. Because of this,
dynamic glutamate measurements using functional MRS (fMRS) may be a more sensitive
early marker in treatment outcome in schizophrenia. Functional MRS uses spectral
acquisitions at specific time points to track changes in human brain metabolites in
response to a functional stimulus. Any abnormalities in glutamate or GSH dynamics in
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individuals with schizophrenia and within their symptom subgroups may reveal a clearer
picture of the specific mechanisms responsible for the full range of schizophrenia
symptoms.
Conventional MRS sequences use a short or “short-as-possible” echo time to minimize
the T2 relaxation and J-dephasing effects. However, a recent study by Wong et al.
(2018)19 examined an array of echo times and identified an optimum TE value for in vivo
glutamate measurement for the 7.0-Tesla semi-LASER sequence to be near TE = 105ms.
This chapter presents a preliminary study to determine whether the conventional short
echo time or the proposed longer echo time would be more appropriate in detecting the
glutamate and GSH dynamics in an fMRS paradigm. We believe this tool is necessary to
investigate in healthy individuals before introducing to a patient population. In this work,
we implement an fMRS paradigm using the color-word Stroop task with one activation
block and a recovery block that is twice the length of the activation block to observe
metabolite recovery behaviors. We expect that both short and long echo times will show
significant increases in glutamate and GSH upon functional activation and that both
metabolite levels will return to baseline within the recovery period timeframe.

2.2 Methods
2.2.1 Participants
Twelve healthy control volunteers were recruited for this study who gave informed
written consent according to the guidelines of the Human Research Ethics Board for
Health Sciences at the University of Western Ontario (Appendix A). Though a patient
population was not included in this particular work, all healthy controls were matched
with our first-episode schizophrenia recruits for age, gender and parental socio-economic
status in order to allow inclusion into the healthy cohort of Chapter 3. Screening was
done on each participant for any significant head injury, major medical illness, or
magnetic resonance imaging (MRI) contraindications.
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2.2.2 Functional Magnetic Resonance Spectroscopy
All fMRS measurements were made at the Centre for Functional and Metabolic Mapping
(CFMM) at the University of Western Ontario using a Siemens MAGNETOM 7-Tesla
MRI scanner along with a head-only radiofrequency coil having 8 transmit channels and
32 receive channels. A two-dimensional turbo spin echo sequence obtained in the sagittal
direction (37 slices, TR=8000ms, TE=70ms, flip-angle (α)=120°, thickness = 3.5mm,
field of view = 240×191mm, echo-train length = 7) was used as reference to place a 2.0 x
2.0 x 2.0 cm (8cm3) 1H-MRS voxel on the bilateral dorsal anterior cingulate cortex
(dACC) where robust activation was observed based on previous work using the same
color-word Stroop task20,21.
One short (TE=60ms) and one long (TE=100ms) echo time was used for each scan
session using the semi-LASER 1H-MRS pulse sequence (TR=7500ms, bandwidth =
6000Hz, N = 2048). For the purpose of this study, descriptions of ‘short’ or ‘long’ echo
times were chosen based on minimum echo time available and falling within the range of
glutamate’s optimal echo times found by Wong et al. (2019)19, respectivelya. Using the
shortest echo time aimed to maximize the signal by minimizing signal lost to T2
relaxation while using the long echo time minimized glutamate signal loss due to Jdephasing of glutamate’s MNPQ multiplet and minimized macromolecular signal
contributions. Localized B0 and B1 shimming, frequency and power calibrations were
completed before each data set collection. For each echo time, 128 channel-combined
spectral averages were acquired, each of which were water-suppressed using the VAPOR
preparation sequence. A water-unsuppressed spectrum was also acquired to use as
reference for spectral post-processing and quantification.
The fMRS paradigm of both echo times consisted of the same four-minute by four-block
model. The first block, labeled ‘Rest’, measured resting metabolite levels. The second

a

It is understood that the expressions “short” and “long” used to describe echo times have different
meanings in other contexts and that an echo time of 60ms could be considered long relative to the T 2 of
human brain metabolites or extremely long in the context of NMR measurements in solids. Here, it is called
short only in relation to the even longer optimal echo time for glutamate.
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block, labeled ‘Stroop’, measured metabolite changes in response to functional activation
by the color-word Stroop task. The third and fourth blocks were the ‘Recovery 1’ and
‘Recovery 2’ blocks to observe the recovery behaviors of metabolite levels after the
cognitive stimulus was removed. The order of echo times for scanning was randomized
into equal proportions with approximately one minute between each scan to allow set-up
of sequence as well as letting participants know of the upcoming sequence. Volunteers
were not taken out of the scanner during the entirety of the scan session and adjustments
were not necessary between echo time changes.

2.2.3 Cognitive Stimulus: Color-Word Stroop Task
PsychoPY22 was used to implement a color-word Stroop task as the functional activation
method for our fMRS paradigm. Volunteers were given a hand-held controller with four
colored buttons (yellow, red, green, blue) to be used to respond to one of four categories
of words they saw on a projected screen of 50% gray background within the MR scanner:
congruent, incongruent, word-only, color-only. This protocol was chosen based on
pervious work by Taylor et al. (2015) that showed reliable activation of the anterior
cingulate19. The instructions given to subjects were to respond, using the controller, to the
color that they saw on the screen, regardless of what the actual word spelled out. The
only condition where volunteers would press what the word actually spelled out would be
the ‘word-only’ category in which no color (white text) would be presented with the text.
Each word stimulus was presented for 2s followed by a cross fixation for 1s. This
protocol lasted for four minutes during the ‘Stroop’ block of the fMRS paradigm. Each of
the other four-minute blocks were simple cross fixations with instructions to keep the
mind as blank as possible to simulate as close to a true resting state that could be
observed during this protocol. To ensure that all participants understood and were able to
perform the Stroop task, an 80% response accuracy threshold was required during a
practice session held in a room near the MRI suite prior to starting the scanning session.
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2.2.4 Spectral Post-Processing
For each echo time, the 128 frequency- and phase-corrected spectra were sequentially
grouped by 32 spectra each, then averaged, to produce 4 final spectra representing each
block of the fMRS paradigm23. These 4 spectra underwent QUALITY Eddy Current
Correction (QUECC)24 post-processing, with 400 QUALITY (quantification improvement
by converting lineshapes to the Lorentzian type) points, to reduce any linewidth distortions

and the Hankel Singular Value Decomposition (HSVD) water removal to remove any
residual water signal between 4.2ppm and 5.7ppm. Afterwards, each spectrum ran
through fitMAN19,25, a spectral fitting routine that uses echo time-specific templates,
modelled with PyGAMMA28, in a Levenberg-Marquardt iterative, non-linear
minimization algorithm in the time domain.
Eighteen brain metabolites included in the fitting template were: alanine, aspartate,
choline, creatine, 𝛾 -aminobutyric acid (GABA), glucose, glutamate, glutamine,
glutathione, glycine, lactate, myo-inositol, N-acetyl aspartate, N-acetyl aspartyl
glutamate, phosphorylethanolamine, scyllo-inositol, and taurine. Macromolecules were
added in the fitting template for only TE=60ms using fourteen Lorentzian lineshapes
constrained and fixed for relative amplitudes and linewidths between macromolecule
resonances. A single phase parameter was used for all macromolecular resonances. The
water unsuppressed spectrum was fit as well, using fitMAN, into a single peak for use
during quantification calculations.
Metabolite concentrations were quantified using Barstool19 through voxel locations
mapped onto 0.75mm isotropic T1-weighted images collected using an MP2RAGE
sequence (TR=6000ms, TI1=800ms, TI2=2700ms, flip-angle 1 (α1)=4°, flip-angle 2
(α2)=5°, FOV=350mm×263mm×350mm, Tacq=9min. 38secs, iPATPE=3 and 6/8 k-space),
for each participant. Gray matter, white matter, and CSF tissue fractions in the voxel
were calculated by partial volume segmentation to correct for tissue-specific T1 and T2
relaxations during quantification.
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2.2.5 Statistical Analysis
Mean metabolite concentrations and standard deviations were calculated for glutamate
and glutathione at both echo times. Paired heteroscedastic t-tests were used to compare
means of each metabolite at short and long echo time. Four measures were used to
compare the quality of signal and quantification between short and long echo time. First,
signal-to-noise ratio (SNRNAA) was calculated using the frequency domain amplitude of
the NAA CH3 peak of each spectrum and dividing it by the standard deviation of the
noise in the last 32 points most upfield of the spectrum. Second, the linewidth, using fullwidth-at-half-max (FWHM), of the water-unsuppressed spectra was calculated. Third,
Cramer-Rao lower bound values were computed using Barstool19. Lastly, group
coefficient of variation was calculated by dividing the standard deviation of metabolite
concentration from each individual of the group by the group’s mean metabolite
concentration.
To assess any differences in effect at the dynamic level, metabolite concentration
percentage changes were calculated using
%∆[𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒] =

[𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒]−[𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒]𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
[𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒]𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒

× 100%,

where [metabolite] is the concentration of the metabolite at the time of interest during the
Stroop paradigm and [metabolite]baseline is the concentration of the metabolite acquired
from

the

first

post-processed

spectral

average.

Two-sample

equal

variance

(homoscedastic) t-tests were used to calculate any significant differences in metabolite
concentration percentage changes between the two echo times.
Lastly, to investigate the strength of co-occurrence between changes of the two
metabolites, Pearson correlation analysis was performed between individual glutamate
and glutathione concentrations across all four time-points of the fMRS paradigm (Rest,
Stroop, Recovery 1, Recovery 2). All statistics were performed using SPSS26.
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2.3 Results
2.3.1 Spectral Fit, Quality, and Quantification
A sample voxel positioning in the bilateral dorsal ACC is shown in Figure 2-1. Figure 2-2
and Figure 2-3 show sample fittings of frequency and phase corrected spectra along with
a detailed breakdown of metabolite components at TE=60ms and TE=100ms,
respectively, both from the same volunteer.

Figure 2-1 Voxel position
A 2cm x 2cm x 2cm voxel (red) placed in the dorsal anterior cingulate cortex (ACC)
in the sagittal (left), transverse (middle), and coronal (right) view.

28

Figure 2-2 Fit components of a human brain spectrum at TE=60ms
The sum of individual metabolite spectral signatures produces the overall spectrum
observed. The bolded black line represents the final fit spectrum overlaid on the raw
data (light grey) from a participant of this study. Individual spectral components
are shown below the fitted spectrum. A 1Hz exponential filter was applied for
display only.
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Figure 2-3 Fit components of a human brain spectrum at TE=100ms
The sum of individual metabolite spectral signatures produces the overall spectrum
observed. The bolded black line represents the final fit spectrum overlaid on the raw
data (light grey) from the same participant as Figure 2-2. Individual spectral
components are shown below the fitted spectrum. A 1Hz exponential filter was
applied for display only.

Four measures comparing spectral quality between TE=60ms and TE=100ms are
highlighted in Tables 2-1, 2-2, and 2-3. The water linewidth (LWW) revealed no
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significant difference between TE=60ms (M=7.25, SD=1.14) and TE=100ms (M=6.92,
SD=1.24); t(22) = 0.686, p = 0.50 (Table 2-1). Likewise, the coefficients of variation
were not significantly different between the short and long echo times (Table 2-2).
Cramer-Rao lower bound (CRLB) values were significantly lower for glutamate (t(94) =
10.204, p < 0.001) but significantly higher for glutathione (t(94) = -8.443, p < 0.001) at
TE=100ms (M=3.24, SD=0.77; M=9.35, SD=2.00) compared to TE=60ms (M=6.06,
SD=1.76; M=6.33, SD=1.47) (Table 2-3).

Table 2-1 Signal-to-noise ratio (SNRNAA) and linewidth (LWW) of spectra
Mean SNRNAA and LWW (N=12) calculated from average of total fMRS data for
TE=60ms and TE=100ms, with standard deviation.

Table 2-2 Coefficient of variation for each block of fMRS paradigm
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Coefficient of variation (CV) expressed as a percentage for glutamate and
glutathione at TE=60ms and TE=100ms. Comparison of CV between the two echo
times are shown for each fMRS paradigm block.

Table 2-3 Cramer-Rao lower bound (CRLB) of each metabolite
Mean CRLB, expressed as a percentage, for glutamate and glutathione
concentration estimates at TE=60ms (N=12) and TE=100ms (N=12) across all fMRS
blocks, with standard deviation.

2.3.2 Metabolite Concentration
Glutamate and glutathione concentrations, during short and long echo times, for the four
blocks of the 1H-fMRS paradigm are summarized in Table 2-4. Pairwise comparison of
adjacent blocks revealed significant decrease in glutamate concentration (t(11) = 4.138, p
< 0.005) from Recovery 1 (M=6.64, SD=1.29) to Recovery 2 (M=6.35, SD=1.13) at
TE=100ms as well as significant decrease in glutathione concentration (t(11) = 2.416, p <
0.05) from Rest (M=2.79, SD=0.40) to Stroop (M=2.64, SD=0.47) for TE=60ms. A
strong trend toward increasing glutamate levels (t(11) = -2.012, p = 0.07) was also
observed between Stroop (M=6.47, SD=1.10) and Recovery 1 (M=6.64, SD=1.29) at
TE=100ms.
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Table 2-4 Pairwise comparison of glutamate and glutathione concentrations for
adjacent blocks
Mean concentrations, with standard error of means, for glutamate and glutathione
across all four fMRS paradigm blocks at TE=60ms (N=12) and TE=100ms (N=12).
The p-value of a paired two-sample t-test comparing blocks is also presented.
Statistically significant values are bolded.

Concentration time-course plots are shown for glutamate (Figure 2-4) and glutathione
(Figure 2-5). Between TE=60ms and TE=100ms, each of the four blocks of the 1H-fMRS
paradigm (Rest, Stroop, Recovery 1, Recovery 2) had significantly different glutamate
concentration estimates (F = 139.756, d.f. = 1,11, p < 0.001). There was no effect of time
(F = 0.876, d.f. = 3,9, p = 0.490) as well as time × echo time interaction (F = 1.386, d.f. =
3,9, p = 0.309). Stroop blocks were not significantly different compared to Rest blocks
for both TE=60ms (p = 0.431, Table 2-4) and TE=100ms (p = 0.460, Table 2-4).
Similarly, between the two echo times, glutathione concentrations were significantly
different (F = 165.108, d.f. = 1,11, p < 0.001) across all four time-points. No effect of
time (F = 1.748, d.f. = 3,9, p = 0.227) or time × echo time interaction (F = 1.836, d.f. =
3,9, p = 0.211) was observed. The Stroop block was significantly different from the Rest
block for TE=60ms (p < 0.05, Table 2-4) but not for TE=100ms (p = 0.181, Table 2-4).
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Figure 2-4 Glutamate concentration estimates
Plot of mean concentrations (mM), with standard error of means, of glutamate
across the fMRS paradigm at TE=60ms (N=12, blue) and TE=100ms (N=12,
orange). The shaded region highlights the 4 minutes of functional activation using
the color-word Stroop task. (Note: the y-axis does not begin at 0 for graphical
purposes and may make small absolute differences appear larger.)
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Figure 2-5 Glutathione concentration estimates
Plot of mean concentrations (mM), with standard error of means, of glutathione
across the fMRS paradigm at TE=60ms (N=12, blue) and TE=100ms (N=12,
orange). The shaded region highlights the 4 minutes of functional activation using
the color-word Stroop task. (Note: the y-axis does not begin at 0 for graphical
purposes and may make small absolute differences appear larger.)

2.3.3 Metabolite Percentage Changes
Glutamate and glutathione concentration dynamics, relative to resting baseline (block 1),
are plotted in Figure 2-6 and Figure 2-7, respectively. Glutamate dynamics were not
significantly different across the four blocks between TE=60ms and TE=100ms (F =
0.541, d.f. = 1,11, p = 0.477). Additionally, no effect of time (F = 1.819, d.f. = 2,10, p =
0.212) or time × echo time interaction (F = 3.170, d.f. = 2,10, p = 0.086) was observed.
Glutathione dynamics were significantly different between the two echo times across all
time points (F = 4.939, d.f. = 1,11, p < 0.05). There was no significant effect of time (F =
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1.971, d.f. = 2,10, p = 0.190) or time × echo time interaction (F = 0.325, d.f. = 2,10, p =
0.730).

Figure 2-6 Dynamic glutamate concentration changes
Plot of mean concentration changes (%) relative to baseline measurements, with
standard error of means, of glutamate across the fMRS paradigm at TE=60ms
(N=12, blue) and TE=100ms (N=12, orange). The shaded region highlights the 4
minutes of functional activation using the color-word Stroop task and the bolded
black line indicates the zero line.
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Figure 2-7 Dynamic glutathione concentration changes
Plot of mean concentration changes (%) relative to baseline measurements, with
standard error of means, of glutathione across the fMRS paradigm at TE=60ms
(N=12, blue) and TE=100ms (N=12, orange). The shaded region highlights the 4
minutes of functional activation using the color-word Stroop task and the black
bolded line indicates the zero line.

2.3.4 Metabolite Correlation
A plot of glutamate concentrations versus glutathione concentrations of each individual
for all four time-points of the fMRS paradigm are shown in Figure 2-8. Pearson
correlation values at TE=60ms for Rest, Stroop, Recovery 1, and Recovery 2 are r =
0.413, p = 0.182; r = 0.556, p = 0.061; r = 0.541, p = 0.070; and r = 0.615, p = 0.033,
respectively. Pearson correlation values at TE=100ms for Rest, Stroop, Recovery 1, and
Recovery 2 are r = 0.859, p < 0.001; r = 0.555, p = 0.061; r = 0.654, p = 0.021; and r =
0.561, p = 0.058, respectively.
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Figure 2-8 Glutamate-glutathione concentration correlation
Correlation between glutamate concentrations (mM) and glutathione concentrations
(mM) for (a) Rest, (b) Stroop activation, (c) Recovery 1, and (d) Recovery 2 blocks.
Dots indicate individual plots of glutamate versus glutathione concentration and
dotted lines represent correlation at TE=60ms (N=12, blue) and TE=100ms (N=12,
orange). (Note: the x- and y- axes do not begin at 0 for graphical purposes.)

2.4 Discussion
The main goal of this work was to determine whether a longer echo time or shorter
conventional echo time for the semi-LASER MRS sequence would be more appropriate
for investigating human brain glutamate and glutathione dynamics in response to a
functional task. This work was able to support the finding of Wong et al. (2018)19 that the
conventional idea of shortest possible echo times in MRS yielding greatest signal
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preserved in metabolite detection is not always true. Although the overall signal detected
may be higher for shorter echo times, when studying specific metabolites that have
complicated J-coupling evolution, such as glutamate, it is necessary to take into
consideration the rephasing of peaks that lead to maxima of signal amplitude at later echo
times. This is indeed what was observed as the longer, optimized, echo time (TE=100ms)
was just as efficient, if not better, for overall and specific metabolite detection compared
to a shorter echo time (TE=60ms). In terms of answering our main objective, the longer
echo time was determined more suitable for observing dynamic metabolite levels for
several reasons. First, the group coefficients of variation were not statistically different
between short and long echo time data. Although this does not directly point towards
long echo time superiority, it does provide a strong basis that optimally long echo time
MRS does not necessarily mean losing important and valuable signal. Second, the
Cramer-Rao lower bound (CRLB) values were significantly lower for glutamate at
TE=100ms, with glutathione CRLB values still remaining in acceptable range. Finally,
longer echo time MRS has the advantage of fully decayed macromolecular signals,
simplifying spectral fitting and quantification and eliminating macromolecular overlap
with signal components from other metabolites.
Apart from signal quality, we investigated the viability of our functional MRS tool to
confirm that glutamate and glutathione dynamics can be detected using long echo time
MRS and that it can provide relevant insight into glutamate and glutathione regulation in
the brain. Resting glutamate and glutathione concentrations obtained from this work
agreed with current literature27. We observed a significant difference in concentration
across all four fMRS paradigm blocks between short and long echo time for both
glutamate and glutathione. This is probably partially attributed to macromolecular
contribution in the short echo time spectra producing overestimation of metabolites in our
spectral fitting and quantification of glutamate and glutathione. Since glutamate and
glutathione are metabolites that have small signal contribution, due to amplitude splitting
among multiple peaks and low concentration, respectively, overestimation may
contribute to significantly different values of concentration estimates. More likely
explanations for the significant difference in metabolite concentration between the two
echo times are that the spectral quantification approach does not account for metabolite
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signal yield or that correction for T1 and T2 of voxel tissue compartments may require
further improvements.
Positive Pearson correlation observed across all four fMRS paradigm blocks between
glutamate concentrations and glutathione concentrations may reflect the brain’s normal
protective response to increasing oxidative stress resulting from excitatory activation.
Most importantly, dynamic glutamate and glutathione measurements proved to be
insightful in studying non-static metabolites in the brain. Upon first look at concentration
comparisons of short and long echo time, for both glutamate and glutathione, all time
points yielded significant difference in quantification. However, using the resting state
measurements to calculate dynamic changes in these metabolites, we found no significant
difference in glutamate and glutathione regulation during the fMRS paradigm (except for
Stroop block for glutathione).
Limitations of this work include lack of significant activation for glutamate and
glutathione during the color-word Stroop task as was demonstrated in our previous
work21. This may be as a result of using different MRS pulse sequence and parameters for
this work as well as having first-episode patient-matched healthy volunteers for this
study. Another less likely explanation is that the cognitive Stroop task may not be as
stimulating due to quick learning effects in our set of volunteers and may require a
stronger functional stimulus to observe significantly detectable change in metabolites.
Also, the order of scan (TE=60ms followed by TE=100ms and vice versa) may affect the
comparison of metabolite levels between echo times due to what we believe might be a
learning effect. Repetition of any task promotes familiarity and can reduce the stimuli
effect that we can measure. In our study, 3 of 12 individuals had the TE=60ms scan first
followed by the TE=100ms and 9 of 12 individuals had the TE=100ms followed by the
TE=60ms. This unbalanced proportion of scan order was due to removing participants
from our data set who did not meet one or more of our inclusion criteria for data analysis,
and may affect our TE=60ms spectra. An additional limitation of this study was the
observation of a quantification accuracy bias possibly due to our approach for
determining correction factors for relaxation weighting of the unsuppressed water signal
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used as a concentration reference. Inaccurate estimates of water T1 and T2 for each tissue
at each echo time may explain the noticeable differences observed in concentration
estimates between measurements at TE=60ms and TE=100ms. Lastly, because every
brain looks different, it is not possible to place MRS voxels in precisely the same
normalized space in real-time across all participants. It is probable that the voxel
placements in this study (and other MRS studies) do not overlap completely but may
perhaps be improved using fMRI guidance to include the entire functionally relevant
region of the brain.
Future works include application of our long echo time fMRS paradigm in clinicallydriven research setting, specifically in first-episode schizophrenia (FES), to investigate if
dynamic measurements of glutamate and glutathione can be an effective early marker to
help stratify the different subgroups within FES. As well, because fMRS is a relatively
novel tool, this work can be extended and refined by increasing the number of
participants, especially with a more balanced ratio of echo time scan order. Different
stimuli to test activation responses using fMRS is another foreseeable venue of
exploration.

2.5 Conclusion
Functional MRS is an exciting tool that still has areas of potential development and
refinement for future applications. Our observations will only be as good as the tools we
use, especially the right tools. This work was an exploration of attempting to identify the
right tools by demonstrating that using optimized long echo time fMRS methods are atleast equivalent to conventionally shorter echo time sequences for observing dynamic
changes of glutamate and glutathione in the human brain, with the added advantage of
simplifying spectral modeling due to removal of macromolecular contribution.
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Chapter 3

3

Dynamic glutamate and glutathione measurements in
first-episode schizophrenia using 7-Tesla

3.1 Introduction
Schizophrenia is a neurodevelopmental illness that affects the lives of approximately one
percent of the population in North America and worldwide1,2. It is characterized by a
highly variable combination of positive, negative and cognitive symptoms of varying
severity that brings about a sort of uniqueness to each individual with the illness3-5. While
positive symptoms include hallucinations, delusions, and other traits that would otherwise
not be present in healthy individuals, negative and cognitive symptoms comprise traits
that appear absent or lacking, such as social withdrawal, apathy, lack of emotions, or
even difficulty with attention and decision making. Currently, there is no cure for
schizophrenia as the etiology and pathophysiological mechanisms of schizophrenia are
unclear. Although treatment options do exist, the first line of treatment, often
antipsychotics, has only been shown to effectively help manage the positive symptoms of
schizophrenia, leaving approximately 30% of individuals with schizophrenia untreated
for negative and cognitive symptoms and resistant to initial treatment6-9. The common
practice today is that only after several unsuccessful anti-psychotic treatment trials would
individuals be regarded as treatment-resistant and prescribed a drug called Clozapine.
Clozapine has been shown to be effective in treating the negative and cognitive
symptoms of schizophrenia, but due to its adverse side effects, it is often viewed as the
last line of treatment6. This poses a major challenge because earlier treatment upon onset
has been shown to drastically improve patient treatment outcome but presently, there are
no tests to definitively know upon first presentation whether someone would be
treatment-resistant or not. For treatment-resistant individuals, this translates to delayed
effective treatment and having to endure any side effects from the ineffective antipsychotic drugs.
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Looking at neurotransmitter abnormalities has been a great step forward into
understanding the possible mechanisms responsible for schizophrenia symptoms10. For
example, dopamine has been found to be clearly involved in schizophrenia as the
effectiveness of anti-psychotic medication was found to be correlated with the
medication’s ability to block D2 dopamine receptors11. Also, dopamine agonists were
found to be able to reproduce major positive symptoms of schizophrenia such as
hallucinations and delusions12. This begs to consider the possibility that other
neurotransmitters or brain metabolites could be responsible for the negative and cognitive
symptoms of schizophrenia, which would also help us understand why dopamine-based
medication seems to be effective mostly for positive symptoms of schizophrenia. Some
convincing findings to support this possibility is that Clozapine has a low dopamine
receptor occupancy as well as that drugs blocking the N-methyl-D-aspartate (NMDA)
glutamate receptors, such as phencyclidine (PCP) and ketamine, are able to reproduce the
full range of positive, negative and cognitive symptoms when administered to both
healthy individuals and exacerbate the symptoms of those already with schizophrenia13,14.
Two brain metabolites of interest are glutamate and glutathione. Glutamate is the brain’s
main excitatory neurotransmitter and due to signs of NMDA glutamate receptor
involvement in schizophrenia symptoms, has been one of the major metabolites under
investigation13-15. Glutathione in humans functions as an anti-oxidant and helps reduce
oxidative stress. The onset of schizophrenia, typically in adolescence or early adulthood,
may be explained by glutamate’s involvement in mediating puberty as the main
excitatory neurotransmitter16 with glutathione acting as a physiological reservoir of
glutamate neurotransmission17,18.
With the availability of magnetic resonance imaging (MRI) scanners, in-vivo molecular
concentrations of brain metabolites can be quantified using a technique called magnetic
resonance spectroscopy (MRS). Using the magnetic field strength of the MRI scanner,
different brain metabolites will experience extremely small differences in the main field
strength due to shielding provided by motion of their own electrons and influence of
electron clouds of neighbouring atoms within the same molecule. This small difference is
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enough for us to separate and identify the different resonant frequency of signals received
from different metabolites.
Much literature has been devoted to using MRS in the study of the brain’s major
metabolites19. One difficulty of MRS studies is that some metabolites have overlapping
resonances with one another, such as glutamate with glutamine, which makes spectral
separation more difficult for accurate quantification19,21. Also, those metabolites that exist
in very low concentrations may be hard to detect using low field MRI and so a high-field
MRI system provides much benefit for metabolite detection and quantification19-22.
Building from standard MRS protocols, functional MRS (fMRS) has been an emerging
tool to track changes in brain metabolite in response to an external stimulus23,24. The
benefits of fMRS is that since every individual vary in resting brain metabolite levels, it
is more appropriate to observe an individual’s response based on their own base levels
rather than comparing the resting states of individuals within a sample group. Another is
that it allows standardization of the activation state during acquisition, which is not
traditionally done in standard MRS, and provides more explanatory power regarding
underlying metabolic abnormality, while still allowing the traditional comparisons.
The current state of fMRS research shows that the magnitude of changes in metabolite
levels can be significantly different based on which stimulus is presented to subjects 25-28.
Hence, when studying schizophrenia or illnesses of the mind, the proper stimulus is
necessary that could potentially reveal difference in brain response between individuals
who are healthy and ill. A stimulus and response too strong might not reveal much
separation or distinction between the two groups, whereas a weak stimulus may not
reveal anything at all. Furthermore, when introducing a task, it is necessary that patients
can perform almost equally as well as controls so that differences in metabolite levels can
be attributed to differences in metabolism rather than performance levels.
This work suggests improvements to previous works as well as offers a novel method for
studying glutamate and glutathione in healthy and schizophrenic individuals using fMRS.
MRS work usually involves resting states that have been paid little effort to control or
standardize the cognitive activity of participants, which may affect metabolite levels even
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in the resting state29. Basic fMRI works show that even thoughts of actions, without the
action itself, is enough for parts of the brain to be stimulated30,31. This work includes an
fMRS protocol with a more controlled cognitive state during both resting and active
periods. Secondly, conventional MRS pulse sequences employ a short echo time to
minimize J-coupling and T2 relaxation effects. Along with results from Chapter 2 of this
thesis, a recent work suggests and shows that a longer echo time is optimal for glutamate
detection for the semi-LASER pulse sequence, adding to the benefit of reduced
macromolecular contribution in the acquired spectra32. This work will utilize the optimal
echo time for glutamate and glutathione detection. Our team’s previous glutamate fMRS
work in schizophrenia22,26 using a cognitive paradigm incorporated observations from
three non-activated blocks interleaved by two activation blocks in medicated patients
with schizophrenia. Due to the possible conflicting behaviors of glutamate activation and
glutamate recovery from repeated cognitive activation, we proposed extended recovery
periods in future works to understand the activated and recovery behaviors more
accurately. Building on this past work, we will investigate not only the stimulus response
behavior of glutamate and glutathione, but also a prolonged recovery behavior after the
stimulus has been removed in never-medicated patients with first-episode schizophrenia.
In this work, we propose an fMRS paradigm using the color-word Stroop task with one
activation block and a recovery block that is twice the length of the activation block to
observe metabolite recovery behaviors. Based on Taylor et al. (2015)’s work22, we
predict that the first-episode schizophrenia population will have a reduced and delayed
glutamate and glutathione change response to the cognitive task stimulus compared to a
healthy control population and that the recovery of both metabolites to baseline be slower
in the first-episode schizophrenia population.

3.2 Methods
3.2.1 Participants
Twenty never-medicated first-episode schizophrenia and 25 healthy control volunteers
were included in this study. All first-episode schizophrenia volunteers satisfied category
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A of DMS-5 Schizophrenia33 as diagnosed by a psychiatrist and trained assistant and
were rated using PANSS-8 scores4. Patient volunteers were recruited from PEPP London
(Prevention and Early Intervention Program for Psychoses, London, Canada) and healthy
control volunteers were recruited through word of mouth while being patient-matched for
age, gender and parental socio-economic status. All participants were screened for any
other psychiatric disorder, significant head injury, major medical illness, or magnetic
resonance imaging (MRI) contraindications and gave informed written consent according
to the guidelines of the Human Research Ethics Board for Health Sciences at the
University of Western Ontario.

3.2.2 Functional Magnetic Resonance Spectroscopy
Measurements were acquired on a Siemens MAGNETOM 7-Tesla MRI scanner using an
8-channel transmit/ 32-channel receive, head-only, radiofrequency coil at the Centre for
Functional and Metabolic Mapping at the University of Western Ontario. A 2.0 x 2.0 x
2.0 cm (8cm3) 1H-MRS voxel was placed on the bilateral dorsal anterior cingulate cortex
(dACC) using a two-dimensional anatomical imaging sequence in the sagittal direction
(37 slices, TR=8000ms, TE=70ms, flip-angle (α)=120°, thickness = 3.5mm, field of view
= 240×191mm). Voxel positions were set in the area of the dACC where activation was
observed based on previous fMRI results that used the same color-word Stroop task26. As
well, this area of the brain is part of a larger brain circuit responsible for attention and
conflict management, called the basal-ganglia-thalamo-cortical (BGTC) circuit, and is
believed to play a role in negative symptoms observed in schizophrenia when circuit
abnormalities arise34. A total of 128 channel-combined, water-suppressed spectral
averages were acquired using the semi-LASER 1H-MRS pulse sequence (TR=7500ms,
TE=100ms, bandwidth = 6000Hz, N = 2048) during each scan session. Water
suppression was achieved using the VAPOR preparation sequence and a waterunsuppressed spectrum was also acquired as a concentration and lineshape deconvolution
reference. Prior to each data set acquisition, localized B0 and B1 shimming, power and
frequency calibrations were made. The functional paradigm implemented had four blocks
of spectral acquisition using the color-word Stroop cognitive task. The first block (Rest)
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measured resting metabolite levels, the second block (Stroop) measured functional
activation in response to the Stroop task, the third block (Recovery 1) measured the
recovery behavior of metabolite levels once the Stroop stimulus was removed, and the
fourth block (Recovery 2) was an added recovery block to examine the recovery behavior
longer. Each block was implemented for four minutes.

3.2.3 Cognitive Stimulus: Color-Word Stroop Task
Before scanning, subjects were introduced to the color-word Stroop task and given
specific instructions to follow during the functional magnetic resonance spectroscopy
sequence. A four-color (yellow, red, green, blue) button controller was used during the
Stroop block of the paradigm for volunteers to respond as quickly as possible to one of
the four category words they saw on an image with 50% gray background projected on a
screen within the MR scanner: congruent, incongruent, word-only, color-only. Subjects
were asked to respond to the color they saw on the screen, regardless of what the actual
words spelled out except for the ‘word-only’ category where no color (white text) was
presented with the text, in which case, they were asked to respond with the button
associated with the color-word. Cognitive stimuli were presented using PsychoPY35 with
stimulus presented for 2s followed by cross fixation for 1s, and repeated until the next 4minute block of the paradigm. All three blocks apart from the Stroop activation block
(Rest, Recovery 1, Recovery 2) had full 4-minutes each of cross fixation to standardize
the participants’ cognitive state during the resting conditions as much as possible when
observing the resting and recovery behaviors of metabolites. Before going into the
scanner, all subjects went through a practice trial of the Stroop task in a room adjacent to
the MRI suite. To ensure that all participants to be included in the analyses understood
the task and could comparably perform it, an 80% response accuracy threshold was set as
a requirement during practice trials.
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3.2.4 Spectral Post-Processing
Each of the 128 spectral acquisitions was corrected for frequency and phase drifts as
described in Near et al. (2015)36. The corrected spectra were then averaged according to
the fMRS paradigm blocks: the first 32 spectra averaged into one spectrum to represent
the entire Rest block, the next 32 spectra for Stroop, and so on for the Recovery 1 and
Recovery 2 blocks, to give a total of four final averaged spectra. The final four averaged
spectra underwent post-processing using combined QUALITY Eddy Current Correction
(QUECC)37, using 400 QUALITY (quantification improvement by converting lineshapes to
the Lorentzian type) points, to reduce linewidth distortions as well as Hankel Singular

Value Decomposition (HSVD) water removal to remove any residual water signal
between 4.2ppm and 5.7ppm before being fit with fitMAN32,38, a time-domain fitting
algorithm that uses a non-linear, iterative Levenberg-Marquardt minimization algorithm
to echo time-specific prior knowledge templates. The metabolite fitting template included
eighteen brain metabolites: alanine, aspartate, choline, creatine, 𝛾 -aminobutyric acid
(GABA), glucose, glutamate, glutamine, glutathione, glycine, lactate, myo-inositol, Nacetyl aspartate, N-acetyl aspartyl glutamate, phosphorylethanolamine, scyllo-inositol,
and taurine. As well, a single peak was used to fit the water unsuppressed spectrum.
Using Barstool32, tissue-specific (gray matter, white matter, and CSF) T1 and T2
relaxations were corrected through partial volume segmentation calculations of voxels
mapped onto T1-weighted images acquired using a 0.75mm isotropic MP2RAGE
sequence (TR=6000ms, TI1=800ms, TI2=2700ms, flip-angle 1 (α1)=4°, flip-angle 2
(α2)=5°, FOV=350mm×263mm×350mm, Tacq=9min. 38secs, iPATPE=3 and 6/8 k-space).
Finally, metabolite concentration quantifications were calculated using the postprocessed water suppressed and unsuppressed spectra for each participant along with
voxel-appropriate, tissue-specific relaxation time adjustments.
To assess the quality of our acquired data, signal-to-noise ratio (SNRNAA) was calculated
by dividing the amplitude of the NAA CH3 peak in the frequency domain by the standard
deviation of the noise in the last 32 most upfield points of the spectrum. The linewidth
was also calculated using water-unsuppressed spectra and measuring the full-width-athalf-max (FWHM) of the water peak in Hertz (Hz).
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3.2.5 Statistical Analysis
Stroop task accuracy and response times were recorded during scan sessions and were
analyzed for differences between groups using a two-sample unequal variance
(heteroscedastic) t-test for each of the Stroop categories. Heteroscedastic t-tests were also
performed within each group for accuracy and response time to unveil any potential
category effects (congruent vs. incongruent).
For the four-spectra block analysis, means and standard deviations of glutamate and
glutathione concentrations were calculated for each group. The coefficient of variation
was calculated as the ratio of the standard deviation to the mean, expressed as a
percentage, for each metabolite within each subject group. Metabolite concentration
percentage changes through the fMRS paradigm were calculated as
%∆[𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒] =

[𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒]−[𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒]𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
[𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒]𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒

× 100%,

where [metabolite] is the concentration of the metabolite at the time of interest during the
Stroop paradigm and [metabolite]baseline is the concentration of the metabolite acquired
from the first post-processed spectral average. Heteroscedastic t-test was performed for
each metabolite to compare concentration differences between healthy controls and firstepisode schizophrenia at each time point as well as metabolite concentration percentage
changes at each time point between the two groups. Two-sample equal variance
(homoscedastic) t-tests were used to find any significant changes in absolute metabolite
concentration and metabolite concentration percentage changes in relation to time for
each metabolite. Lastly, Pearson correlation analysis was used to test the predictability of
glutamate change to glutathione change in the fMRS paradigm. All statistics were
computed using SPSS39.
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3.3 Results
3.3.1 Stroop Task
All participants included in this study were able to meet the 80% accuracy threshold
during the Stroop task. Mean accuracy and response times for each of the Stroop
categories are shown in Table 3-1. Healthy control volunteers (M=98.700, SD=1.593)
performed the Stroop task with higher accuracy (t(44) = 4.081, p < 0.001) compared to
the first-episode schizophrenia group (M=94.290, SD=5.132). Both healthy control and
patient groups had significantly lower accuracy (t(48) = 3.438, p = 0.001; t(40) = 3.726, p
= 0.001) in the ‘Incongruent’ category (M=95.600, SD=5.649; M=86.430, SD=13.242)
compared to the ‘Congruent’ category (M=99.600, SD=1.384; M=97.620, SD=3.748).
Response times were significantly shorter (t(44) = -2.817, p = 0.007) for healthy controls
(M=72.117,

SD=12.121)

compared

to

first-episode

schizophrenia

(M=83.222,

SD=14.621), and in both healthy control and patient groups, responding to the
‘Incongruent’ stimuli (M=1.054, SD=0.181; M=1.210, SD=0.215) took significantly
longer (t(48) = -4.667, p < 0.001; t(40) = -3.663, p < 0.001) than responding to the
‘Congruent’ stimuli (M=0.833, SD=0.153; M=0.982, SD=0.188).

Table 3-1 Summary of Stroop task performance
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Mean accuracy (%) and response time (s), with standard
deviation, for healthy controls (N=25) and first-episode
schizophrenia (N=21). Values are given for total mean as well
as each of the Stroop categories.

3.3.2 Spectral Quality and Fit
An example of voxel positioning on the bilateral dorsal ACC can be seen in Figure 3-1 as
well as a sample spectral fit using the fitMAN software in Figure 3-2. Individual
metabolite spectra are also shown for metabolites of interest.

Figure 3-1 Voxel position
A 2cm x 2cm x 2cm voxel (red) placed in the dorsal anterior cingulate cortex (ACC)
in the transverse (left), coronal (middle), and sagittal (right) view.
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Figure 3-2 Spectral fit with metabolite components
Sample spectral fit using fitMAN. The bolded black line represents the final fit
spectrum overlaid on the raw data (light grey) from a first-episode schizophrenia
participant of this study. Individual spectral components of metabolites of interest
are shown below the fitted spectrum. A 1Hz exponential filter was applied for
display only.
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Spectral quality assessments were made using SNRNAA (Table 3-2), water spectral
linewidth (Table 3-2), coefficient of variation (Table 3-3), and Cramer-Rao lower bounds
(Table 3-4). There was no significant difference in SNRNAA (t(44) = 0.280, p = 0.780) or
linewidth (t(44) = -1.270, p = 0.211) between the healthy control and first-episode
schizophrenia groups. Coefficient of variation values were only significantly different
between healthy control and first-episode schizophrenia groups in the Recovery 2 block
for glutathione (p < 0.005, F=0.28). Lastly, there were no significant differences (t(182) =
-1.316, p = 0.190; t(182) = -0.416, p = 0.678) between healthy controls (M=3.109,
SD=0.535; M=9.127, SD=1.956) and first-episode schizophrenia cohorts (M=3.218,
SD=0.602; M=9.238, SD=1.609) for glutamate and glutathione CRLB values,
respectively.

Table 3-2 Signal-to-noise ratio (SNRNAA) and linewidth (LWW)
Mean SNRNAA and LWW, with standard deviation, for healthy control (N=25) and
first-episode schizophrenia (N=21) groups.
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Table 3-3 Summary of coefficients of variation (CV)
Glutamate and glutathione coefficients of variation expressed as a percentage (%)
for healthy control (HC) and first-episode schizophrenia (FES) groups. Comparison
of inter-individual CV between the two groups are shown for each fMRS paradigm
block. Statistically significant values are bolded.

Table 3-4 Cramer-Rao lower bound (CRLB) values
Mean CRLB values, expressed as a percentage (%), with
standard

deviations,

from

glutamate

and

glutathione

concentration calculations for healthy control (N=25) and
first-episode schizophrenia (N=21) groups.
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3.3.3 Metabolite Concentration
Table 3-5 summarizes the glutamate and glutathione concentrations across the four fMRS
blocks. A pairwise comparison of adjacent blocks revealed significant decreases in
glutamate concentration between Recovery 1 (M=6.597, SD=1.012) and Recovery 2
(M=6.462, SD=0.997) in healthy controls (t(24) = 2.666, p = 0.014) as well as between
Stroop (M=6.947, SD=1.328) and Recovery 1 (M=6.767, SD=1.360) in the first-episode
schizophrenia group (t(20) = 2.718, p = 0.013). There was also a significant increase in
glutathione concentration between Rest (M=1.482, SD=0.252) and Stroop (M=1.605,
SD=0.212) for healthy controls (t(24) = -2.819, p = 0.009). Strong trend toward
increasing glutamate levels was present between Rest (M=6.809, SD=1.238) and Stroop
(M=6.947, SD=1.328) of first-episode schizophrenia cohorts (t(2) = -1.887, p = 0.074) as
well as a strong trend toward decreasing glutathione levels between Recovery 1
(M=1.667, SD=0.297) and Recovery 2 (M=1.577, SD=0.182) in healthy controls (t(24) =
1.954, p = 0.062).

Table 3-5 Pairwise comparison of glutamate and glutathione concentrations
Mean concentrations, with standard error of means, for glutamate and glutathione
across all four fMRS paradigm blocks for healthy control (N=25) and first-episode
schizophrenia (N=21) groups. Comparison between adjacent blocks are given
between the blocks. Statistically significant values are bolded.
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Time-course plots of glutamate and glutathione concentrations are shown in Figure 3-3
and figure 3-4, respectively. Significantly higher resting glutathione concentration (t(44)
= -2.784, p = 0.008) was observed in first-episode schizophrenia (M=1.736, SD=0.366)
compared to healthy controls (M=1.482, SD=0.252).

Figure 3-3 fMRS glutamate concentration time-course
Plot of mean concentrations (mM), with standard error of means, of glutamate
across the fMRS paradigm for HC (N=25, blue) and FES (N=21, orange). The
shaded region highlights the 4 minutes of functional activation using the color-word
Stroop task. (Note: the y-axis does not begin at 0 for graphical purposes.)
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Figure 3-4 fMRS glutathione concentration time-course
Plot of mean concentrations (mM), with standard error of means, of glutathione
across the fMRS paradigm for HC (N=25, blue) and FES (N=21, orange). The
shaded region highlights the 4 minutes of functional activation using the color-word
Stroop task. (Note: the y-axis does not begin at 0 for graphical purposes.)

3.3.4 Metabolite Dynamics
Glutamate dynamics, relative to resting baseline, showed no significant group difference
between healthy control and first-episode schizophrenia (Figure 3-5). However, healthy
controls had significantly higher glutathione concentration changes compared to the firstepisode schizophrenia group (Figure 3-6) across all non-resting fMRS blocks: Stroop
(t(44) = 2.322, p = 0.025), Recovery 1 (t(44) = 2.908, p = 0.006), and Recovery 2 (t(44) =
2.926, p = 0.005).
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Figure 3-5 fMRS glutamate dynamics
Plot of mean concentration changes (%) relative to baseline measurements, with
standard error of means, of glutamate across the fMRS paradigm for HC (N=25,
blue) and FES (N=21, orange). The shaded region highlights the 4 minutes of
functional activation using the color-word Stroop task.
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Figure 3-6 fMRS glutathione dynamics
Plot of mean concentration changes (%) relative to baseline measurements, with
standard error of means, of glutathione across the fMRS paradigm for HC (N=25,
blue) and FES (N=21, orange). The shaded region highlights the 4 minutes of
functional activation using the color-word Stroop task.

3.3.5 Correlation Analysis
Figure 3-7 show plots of glutamate versus glutathione concentrations of each individual
for the four fMRS blocks. Pearson correlation values for healthy controls for Rest,
Stroop, Recovery 1, and Recovery 2 are r = 0.603, p = 0.001; r = 0.448, p = 0.025; r =
0.507, p = 0.010; and r = 0.521, p = 0.008, respectively. Pearson r for the first-episode
schizophrenia group for Rest, Stroop, Recovery 1, and Recovery 2 are r = 0.700, p <
0.001; r = 0.724, p < 0.001; r = 0.842, p < 0.001; and r = 0.818, p < 0.001, respectively.
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Figure 3-7 Correlation of glutamate and glutathione concentrations
Correlation between glutamate concentrations (mM) and glutathione concentrations
(mM) for (a) Rest, (b) Stroop activation, (c) Recovery 1, and (d) Recovery 2 blocks.
Dots indicate individual plots of glutamate versus glutathione concentration and
dotted lines represent correlation for HC (N=25, blue) and FES (N=21, orange).
(Note: the x- and y- axes do not begin at 0 for graphical purposes.)

3.4 Discussion
3.4.1

Glutamate and Glutathione Concentration

This current study builds upon previous work22,26 to investigate possible glutamate and
glutathione regulation abnormalities in the brain of first-episode schizophrenia cohorts
using a dynamic tool, functional MRS. Our findings indicate that fMRS is more
appropriate than simple resting state MRS for looking at brain metabolites that are highly
dynamic.
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Resting glutamate levels were higher, but not significantly, in FES than HC (t(44) = 0.621, p = 0.538). We did not observe a significant increase in glutamate levels in either
HC (t(24) = -0.582, p = 0.566) or FES (t(20) = -1.887, p = 0.074) in response to the
color-word Stroop task. However, a strong trend toward increased glutamate in FES
during the functional task (t(20) = -1.887, p = 0.074), a significant decrease in glutamate
from the Stroop block to the Recovery 1 block (t(20) = 2.718, p = 0.013) where glutamate
levels returned to near baseline values, as well as visual observation of Figure 3-3
suggests that stronger activation was present in FES than HC. This is also supported by
the Stroop performance where HC performed significantly more accurately (t(44) =
4.081, p < 0.001) and quickly (t(44) = -2.817, p = 0.007) than their FES counterparts
across all categories of the color-word Stroop task. Also, interesting glutamate behavior
was observed in the recovery periods of both HC and FES. As predicted, once the
functional stimulus was removed, glutamate levels returned to baseline levels by the first
recovery period for both groups. However, glutamate concentrations continued to fall
during the second recovery period, falling significantly lower than baseline values for HC
(t(24) = 3.053, p = 0.005). This is a behavior not yet cited in current literature and
perhaps need further exploration. One theory behind this occurrence may be a predictive
compensation effect of the brain’s preparation for subsequent, or near-future, stimuli
activation, which may lead to excitotoxicity from glutamate response.
Glutathione levels at rest were found to be significantly higher (t(44) = -2.784, p = 0.008)
in our FES group (M=1.736, SD=0.366) than in HC (M=1.482, SD=0.252), suggesting
higher than normal levels of oxidative stress present in FES. Furthermore, significant
increase in glutathione concentration in HC (t(24) = -2.819, p = 0.009) but not in FES
(t(20) = 0.828, p = 0.417) may point toward abnormal FES glutathione regulation and
response to oxidative stress from repeated cognitive tasks.

3.4.2

Dynamic Changes in Glutamate and Glutathione

Changes in glutamate levels for FES (~2% concentration increase) during the color-word
Stroop task agree with our own past work using a different pulse sequence22. When
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looking at the dynamic glutamate recovery period, we observe an approximately similar
2% drop in glutamate levels no matter how much or little activation was present during
the Stroop block for both HC and FES. This additional feature of glutamate recovery may
further support the suggestion for a predictive compensation effect in the brain. By
anticipating subsequent cognitive battery from initial stimulus presentation, the brain may
lower its glutamate levels as an adaptive response to prevent potential excitotoxicity from
stimulus-induced glutamate excess.
The fMRS measurements of glutathione show more dramatic changes during the task
paradigm conditions, suggesting that traditional MRS methods would not capture this
information and be confounded by such dynamic effects, making their interpretation even
more difficult. Healthy controls responded strongly (~10% glutathione concentration
increase) to the functional task and presumed associated oxidative stress, and continued
to remain at high levels even after the functional stimulus was removed. This behavior
complements possible compensation effects of glutamate, reflecting the brain’s possible
short-term preparation for further stimuli in the near-future by keeping glutathione levels
active. First-episode schizophrenia glutathione dynamics revealed the opposite, starting
and continuing decline in glutathione levels, strongly suggesting FES participants’ lack of
proper glutathione response and mitigation of oxidative stress.

3.4.3

Correlation

Positive correlation was observed between glutamate and glutathione concentrations
across all four fMRS blocks (Section 3.3.5). Specifically, the resting state correlation is in
alignment with findings of Kumar et al. (2018)40. We also found that the FES group
exhibited much stronger correlation across all time points compared to HC, especially
during the Recovery 1 period (z = -2.07, p < 0.05) and Recovery 2 period (z = -1.83, p =
0.07). One possibility to explain our correlation findings would be that an already
elevated level of glutamate, especially in FES, may lead to active oxidation of glutamate
into glutathione in a self-regulation attempt to prevent excitotoxicity.
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3.4.4

Limitations and Future Work

Several limitations should be addressed. First, lack of significant glutamate activation and
minor discrepancies compared to previous work22 may be due to the completely different
MRS sequence used for this study (semi-LASER vs STEAM), as well as having our echo
time optimized for glutamate detection (based on work from Chapter 2) as opposed to
conventional short echo time parameters. We also note that never-medicated first-episode
schizophrenia cohorts in this study reflect a different volunteer recruitment pool than our
previous study (individuals with chronic schizophrenia, with medication)22, and may
affect our observations. Finally, although 21 FES participants were included in this study,
our FES population was not divided by any symptom or treatment category. It is quite
possible that within different categories, such as dopamine-based first-line medication
responders versus non-responders, or even among affected symptom groups, we may see
new trends and findings of abnormal glutamate and glutathione regulation and behavior
in FES.
Future work will include using follow-up assessment and scan data to retrospectively
group our current fMRS data into appropriate sub-groups. This will reveal if glutamate
and/or glutathione abnormalities can be used as effective early markers for treatment
response outcome in first-episode schizophrenia. Another area to investigate further is the
glutamate recovery behavior mentioned in our analysis. Seeing glutamate levels drop
below resting levels after extended recovery period in both HC and FES has never been
assessed and may reveal insight into glutamate regulation in response to functional tasks
in the human brain while the rest and active period serve more as cognitive status
standardization. Understanding brain glutamate and glutathione dynamics is crucial in
designing proper protocols of study observation and proper physiological models of how
their bulk tissue concentration varies during activation41.
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3.5 Conclusion
In order to be sensitive to metabolite dynamics in the human brain, functional MRS
measurements are more appropriate than traditional MRS, especially if levels of brain
activity during the acquisition are not properly controlled. Although fMRS methodology
is still developing, this work was able to highlight insightful glutamate behavior as well
as abnormal glutathione behavior in first-episode schizophrenia. This work is one step
closer to finding appropriate early markers for symptom treatment outcome in
schizophrenia so that the right medication can be administered to the right patient upon
first presentation into the clinic.
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Chapter 4

4

Conclusion

In this thesis, we aimed to optimize our functional magnetic resonance spectroscopy
protocol for detecting glutamate dynamics in response to a functional task, and to apply
this in a group of never medicated first-episode schizophrenia expecting to reveal
abnormal regulation of glutamate and glutathione compared to patient-matched group of
healthy controls. Contrary to beliefs that the shortest possible echo time is best for
metabolite observation using magnetic resonance spectroscopy, a longer echo time, when
optimized, was found to better highlight the rephasing of signals from specific
metabolites of interest and can be used in a functional MRS setting to detect metabolite
dynamics in response to a functional paradigm. We also found that dynamic MRS
measurements were more appropriate than traditional MRS measurements to reveal
modulation of metabolite levels related to performance of a cognitive activation
paradigm. Dynamic MRS, or fMRS, revealed better controlled differences of glutamate
and glutathione regulation in both resting and active conditions when comparing firstepisode schizophrenia to matched healthy controls. Our finding of prolonged elevation of
GSH suggest that the human brain may a have protective preparation response to
potential near-future stimulation or oxidative stress based on administered cognitive
stimulation.

4.1

Limitations

Though this work presented findings from glutathione dynamics along with glutamate
dynamics, our specific fMRS sequence and echo time for clinical study (Chapter 3) was
optimized for glutamate. Future approaches investigating glutathione, or other related
metabolites such as glutamine and GABA, warrant methods optimized for those specific
metabolites. Perhaps this limitation can lead to work on finding optimized approaches for
best detection of multiple metabolites. Secondly, our current MRS measurements cannot
distinguish between glutamate in the synaptic cleft, which is where glutamate
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abnormalities related to schizophrenia are hypothesized to exist, and glutamate in the
extracellular fluid1,2. Though our functional paradigm alleviates this limitation slightly by
focusing on glutamate regulation, in what we believe is occurring at the level of the
synaptic cleft, instead of resting measurement of glutamate in the entire voxel, our tools
cannot verify precisely that any glutamate abnormalities observed is purely a result of
abnormalities in the synaptic cleft. Thirdly, our studies measured glutamate from only
one part of the brain (dACC) without any other control region. We also were not able to
include another related illness, such as major depressive disorder (MDD), to verify that
any abnormalities observed in the dACC were specific to schizophrenia in the dACC (as
was done in Taylor et al. 20153). Lastly, our current MRS and fMRS analyses are made
on a group-level. Increasing spectral resolution and optimizing metabolite signal
detection are necessary improvements to translate this work from group-level analyses to
individual-level analyses, a tool that would prove valuable for personally targeted care
for patients with schizophrenia.

4.2

Future Works

Future direction of this work will include a longitudinal analysis of fMRS data based on
our FES volunteer population at 6-month, 18-month, and 30-month follow-up
appointments. Treatment outcome measures and symptom response assessments will be
used to retrospectively evaluate the predictive power of the early scan data (0-month,
never-medicated) to discriminate responders from non- responders. Another exciting
avenue of research is the use of glutamate chemical exchange saturation transfer
(GluCEST) as another tool to observe whole brain glutamate levels. This GluCEST
protocol is under development, but once ready, is expected to provide higher metabolite
signals as well as a whole brain perspective of glutamate behavior in response to
cognitive activation.
It is important to continue glutamate and glutathione research in schizophrenia as early
markers for stratifying responders and non-responders could have a disruptive effect on
the current standard of care, especially for patients in the non-responder group. Empirical
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evidence

for

sub-groups

of

schizophrenia

patients

experiencing

different

pathophysiological presentations of schizophrenia4 will help change the face of
antipsychotic treatment to a better targeted treatment for each individual and will help
untangle results and simplify the interpretation of drug trials for glutamate-based
treatment approaches5.
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Appendix B: Supplementary Figures

Appendix B-1. Pairwise comparison of mean glutamate and glutathione signal ratios
(relative to NAA and Cr), with standard error of means, for TE=60ms (N=12) and
TE=100ms (N=12). Statistically significant values are bolded.

Appendix B-2. Pairwise comparison of mean glutamate and glutathione signal ratios
(relative to NAA and Cr), with standard error of means, for HC (N=25) and FES
(N=21). Statistically significant values are bolded.
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Group

Rest
[mM]

Stroop
[mM]

Recovery 1
[mM]

Recovery 2
[mM]

TE=60ms
Alanine
Aspartate
Choline
Creatine
GABA
Glucose
Glutamate
Glutamine
Glutathione
Glycine
Lactate
Myo-inositol
N-Acetyl Aspartate
N-Acetyl-Aspartyl Glutamate
Phosphorylethanolamine
Scyllo-inositol
Taurine

0.13±0.05
1.14±0.20
2.43±0.07
9.44±0.25
2.03±0.24
2.09±0.12
9.31±0.44
0.31±0.15
2.79±0.12
0.27±0.07
0.09±0.05
5.79±0.14
12.15±0.32
0.28±0.08
15.73±0.98
0.21±0.02
3.06±0.61

0.21±0.10
0.97±0.18
2.47±0.07
9.48±0.23
2.31±0.36
2.12±0.12
9.53±0.46
0.25±0.13
2.64±0.14
0.33±0.14
0.21±0.08
5.91±0.16
12.28±0.30
0.21±0.07
14.18±1.13
0.23±0.03
2.93±0.69

0.14±0.07
0.82±0.18
2.43±0.08
9.42±0.22
2.00±0.31
2.03±0.09
9.25±0.40
0.29±0.14
2.73±0.12
0.33±0.09
0.24±0.07
5.74±0.10
12.15±0.31
0.26±0.09
13.31±1.63
0.22±0.02
2.69±0.48

0.16±0.07
0.77±0.26
2.43±0.07
9.30±0.22
1.87±0.38
2.10±0.13
9.34±0.38
0.40±0.19
2.77±0.10
0.39±0.11
0.14±0.09
5.84±0.18
12.06±0.33
0.34±0.11
13.86±1.00
0.22±0.03
3.25±0.46

TE=100ms
Alanine
Aspartate
Choline
Creatine
GABA
Glucose
Glutamate
Glutamine
Glutathione
Glycine
Lactate
Myo-inositol
N-Acetyl Aspartate
N-Acetyl-Aspartyl Glutamate
Phosphorylethanolamine
Scyllo-inositol
Taurine

0.17±0.06
0.00±0.00
2.39±0.09
8.33±0.29
0.00±0.00
0.42±0.10
6.52±0.31
0.98±0.09
1.51±0.07
0.01±0.01
0.06±0.02
4.69±0.21
10.31±0.38
0.03±0.03
2.00±0.64
0.30±0.04
1.22±0.15

0.17±0.04
0.00±0.00
2.39±0.09
8.39±0.29
0.00±0.00
0.38±0.10
6.47±0.32
1.05±0.11
1.61±0.06
0.00±0.00
0.08±0.02
4.71±0.23
10.38±0.38
0.01±0.01
1.50±0.56
0.31±0.04
0.98±0.15

0.19±0.05
0.00±0.00
2.39±0.09
8.31±0.31
0.00±0.00
0.36±0.09
6.64±0.37
1.00±0.08
1.64±0.08
0.00±0.00
0.13±0.03
4.67±0.23
10.39±0.41
0.02±0.02
1.95±0.76
0.29±0.03
1.24±0.13

0.15±0.04
0.00±0.00
2.35±0.10
8.32±0.31
0.00±0.00
0.40±0.09
6.35±0.33
1.05±0.11
1.63±0.08
0.00±0.00
0.09±0.03
4.55±0.22
10.23±0.38
0.02±0.02
1.07±0.52
0.31±0.03
1.03±0.12

Appendix B-3. Mean concentration, with standard error of means, of all
quantifiable metabolites using fitting template for TE=60ms (N=12) and TE=100ms
(N=12).
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Group

Rest
[mM]

Stroop
[mM]

Recovery 1
[mM]

Recovery 2
[mM]

HC
Alanine
Aspartate
Choline
Creatine
GABA
Glucose
Glutamate
Glutamine
Glutathione
Glycine
Lactate
Myo-inositol
N-Acetyl Aspartate
N-Acetyl-Aspartyl Glutamate
Phosphorylethanolamine
Scyllo-inositol
Taurine

0.14±0.03
0.00±0.00
2.47±0.06
8.50±0.18
0.00±0.00
0.43±0.07
6.61±0.19
1.07±0.06
1.48±0.05
0.00±0.00
0.08±0.02
4.67±0.14
10.40±0.23
0.02±0.02
3.40±0.61
0.27±0.02
1.05±0.09

0.18±0.03
0.00±0.00
2.46±0.06
8.56±0.18
0.00±0.00
0.43±0.07
6.63±0.20
1.06±0.06
1.61±0.04
0.00±0.00
0.11±0.01
4.75±0.14
10.45±0.23
0.00±0.00
2.12±0.51
0.29±0.02
0.90±0.09

0.20±0.03
0.00±0.00
2.46±0.06
8.50±0.19
0.00±0.00
0.50±0.09
6.60±0.20
1.03±0.05
1.67±0.06
0.00±0.00
0.10±0.02
4.83±0.15
10.41±0.24
0.01±0.01
2.62±0.58
0.30±0.02
1.09±0.09

0.19±0.03
0.00±0.00
2.37±0.06
8.37±0.18
0.00±0.00
0.44±0.07
6.46±0.20
1.06±0.06
1.58±0.04
0.00±0.00
0.11±0.02
4.62±0.13
10.23±0.22
0.03±0.02
1.90±0.53
0.30±0.02
1.00±0.09

FES
Alanine
Aspartate
Choline
Creatine
GABA
Glucose
Glutamate
Glutamine
Glutathione
Glycine
Lactate
Myo-inositol
N-Acetyl Aspartate
N-Acetyl-Aspartyl Glutamate
Phosphorylethanolamine
Scyllo-inositol
Taurine

0.18±0.04
0.00±0.00
2.58±0.11
9.07±0.36
0.00±0.00
0.46±0.08
6.81±0.27
1.12±0.07
1.74±0.08
0.00±0.00
0.11±0.02
4.82±0.24
10.99±0.38
0.03±0.02
2.51±0.88
0.34±0.03
1.12±0.10

0.21±0.03
0.00±0.00
2.60±0.12
9.15±0.40
0.00±0.00
0.45±0.09
6.95±0.29
1.10±0.07
1.69±0.06
0.00±0.00
0.13±0.02
4.95±0.24
11.11±0.41
0.02±0.01
2.52±0.69
0.32±0.03
1.14±0.11

0.15±0.04
0.00±0.00
2.58±0.12
9.07±0.38
0.00±0.00
0.43±0.09
6.77±0.30
1.06±0.09
1.65±0.07
0.00±0.00
0.13±0.02
4.81±0.23
10.95±0.40
0.04±0.04
3.07±0.85
0.34±0.02
1.09±0.12

0.22±0.03
0.00±0.00
2.54±0.12
9.00±0.38
0.00±0.00
0.44±0.07
6.67±0.27
1.16±0.08
1.65±0.08
0.00±0.00
0.15±0.02
4.54±0.32
10.92±0.40
0.01±0.01
2.13±0.52
0.34±0.03
1.16±0.09

Appendix B-4. Mean concentration, with standard error of means, of all
quantifiable metabolites using fitting template for HC (N=25) and FES (N=21).
Appendix B Supplementary tables and figures
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